Cargando…
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT)
OBJECTIVE: C-reactive protein (CRP) is closely associated with obesity and cardiovascular disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed antidiabetic agents have different effects on CRP; however, the long-term effects of those agents are unknown. RESEAR...
Autores principales: | Kahn, Steven E., Haffner, Steven M., Viberti, Giancarlo, Herman, William H., Lachin, John M., Kravitz, Barbara G., Yu, Dahong, Paul, Gitanjali, Holman, Rury R., Zinman, Bernard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797969/ https://www.ncbi.nlm.nih.gov/pubmed/19808911 http://dx.doi.org/10.2337/dc09-1661 |
Ejemplares similares
-
Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
por: Kahn, Steven E., et al.
Publicado: (2011) -
Review of metformin and glyburide in the management of gestational diabetes
por: Carroll, Dana G., et al.
Publicado: (2014) -
Adherence to Glyburide and Metformin and Associated Factors in Type 2 Diabetes in Isfahan, Iran
por: Farsaei, Shadi, et al.
Publicado: (2011) -
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
por: Home, P. D., et al.
Publicado: (2010) -
Greater omental infarction
por: Bin Mohamed Ebrahim, Mohamed Eftal, et al.
Publicado: (2022)